Clinical and microbiological evaluation of miocamycin activity against group A beta-hemolytic streptococci in pediatric patients. Three years' incidence of erythromycin-resistant group A streptococci.
The authors have evaluated the incidence of Group A streptococci, and the prevalence of erythromycin-resistant strains in the years 1985/86/87 at the I.C.P. of Milan. The minimum inhibitory concentrations (MICs) for erythromycin, penicillin and miocamycin of 40 erythromycin-resistant strains were also studied (MIC50-MIC90 = 4.5-8, 0.015-0.015, 0.041-0.186 micrograms/ml respectively). A clinical trial with miocamycin vs. erythromycin in the elimination of Group A streptococci (67 patients) showed good and comparable efficacy for both the antibiotics.
Borzani
M
M
Dept. of Pediatrics, School of Medicine, University of Milan, Italy.
Varotto
F
F
Garlaschi
L
L
Conio
F
F
Dell'Olio
M
M
Careddu
P
P
D002648:Child; D002675:Child, Preschool; D002986:Clinical Trials as Topic; D004352:Drug Resistance, Microbial; D004917:Erythromycin / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D015643:Erythromycin Ethylsuccinate; D005260:Female; D006801:Humans; D007223:Infant; D007933:Leucomycins / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D015644:Miocamycin; D010406:Penicillins / Q000494:pharmacology; D010612:Pharyngitis / Q000188:drug therapy / Q000382:microbiology; D013297:Streptococcus pyogenes / Q000187:drug effects*
D007933:Leucomycins; D010406:Penicillins; D015643:Erythromycin Ethylsuccinate; D015644:Miocamycin; D004917:Erythromycin